Albright Charles 4
4 · Editas Medicine, Inc. · Filed Aug 10, 2020
Insider Transaction Report
Form 4
Albright Charles
Chief Scientific Officer
Transactions
- Exercise/Conversion
Stock Option (right to buy)
2020-08-06−10,000→ 195,000 totalExercise: $16.51Exp: 2026-09-08→ Common Stock (10,000 underlying) - Exercise/Conversion
Common Stock
2020-08-06$16.51/sh+10,000$165,100→ 38,373 total - Sale
Common Stock
2020-08-06$37.47/sh−10,000$374,700→ 28,373 total - Sale
Common Stock
2020-08-07$34.99/sh−238$8,328→ 28,135 total
Footnotes (4)
- [F1]The exercise and sale was effected pursuant to a 10b5-1 plan adopted by the Reporting Person on May 15, 2020.
- [F2]Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on May 11, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on August 6, 2020. The sale does not represent a discretionary trade by the Reporting Person.
- [F3]This transaction was executed in multiple trades at prices ranging from $34.69 to $35.00. The price reported above reflects the weighted average sale price. The Reporting Person herebyundertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F4]This option was granted on September 9, 2016 and is scheduled to vest over four years with 25% of the shares having vested on August 22, 2017, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through August 22, 2020.